原始来源记录
决策级顶线结果
Dogwood Therapeutics: Halneuron Phase 2b CINP 2026年秋季顶线数据
8-K确认Halneuron在化疗诱导神经病理性疼痛中的Phase 2b试验保持正常推进，已入组164名患者，顶线结果预计2026年秋季发布。此外，FDA已受理SP16 IND，用于Phase 1b CIPPN研究，该研究将于2026年年中开始入组。
关键事实
- 申报时间
- 2026年5月14日 12:50
- 事件
- 顶线结果
- 方向
- 中性
- 来源
- SEC 8-K
- 可信度
- 有来源
- 入组患者
- 164
来源摘录
EX-99.1 2 dwtx-20260514xex99d1.htm EX-99.1 Exhibit 99.1 Dogwood Therapeutics Announces First Quarter 2026 Financial Results - Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 - - FDA acceptance of SP16 Investigational New Drug Application for the treatment of Chemotherapy Induced Pain and Neuropathy – - Announces Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood and its current and former shareholders - ALPHARETTA, Ga., May 14, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced financial results for the